Understanding the implications of the side effect profile of individual antiretroviral drugs as well as the durability of drug regimens has considerable significance in settings where resources and drug options for HIV remain limited. HE2RO has explored these questions through longitudinal patient datasets with a particular interest in the effects of tenofovir upon introduction into the national programme. These analyses are ongoing as guidelines continue to evolve and current projects include a pharmacovigilence study in collaboration with researchers at the University of Cape Town.
The following publications emanate from this project:
HE2RO staff involvedLawrence Long Matthew Fox Denise Evans Dr Mhairi Maskew Kate Shearer
Receive newsletters and keep up to date with developments at HE2RO.